Felty syndrome is characterised by chronic arthritis, splenomegaly and leucopenia. Although anaemia is present in many affected patients, significant haemolysis has not yet been described. While disease-modifying agents do not seem to improve leucopenia and anaemia, splenectomy results in a prompt relief of the haematological manifestations in most cases.1^–3 To date, rituximab has been used in the treatment of three patients with Felty syndrome, and the haematological manifestation was improved in one patient only.4 5

We report on an improvement of both arthritis and haemolysis, but not of neutropenia and thrombocytopenia, …